Literature DB >> 21239871

Bacteremia caused by Corynebacterium amycolatum with a novel mutation in gyrA gene that confers high-level quinolone resistance.

Seoyoung Yoon1, Heejung Kim, Yangsoon Lee, Sinyoung Kim.   

Abstract

Although Corynebacterium amycolatum can cause opportunistic infections, it is commonly considered as contaminant. In this report, we present a case of bacteremia caused by C. amycolatum with a novel mutation in the gyrA gene that confers high-level quinolone resistance to the organism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239871      PMCID: PMC3111041          DOI: 10.3343/kjlm.2011.31.1.47

Source DB:  PubMed          Journal:  Korean J Lab Med        ISSN: 1598-6535


INTRODUCTION

Corynebacterium species except Corynebacterium diphtheriae are part of the normal flora of the skin and mucous membrane and occur as common contaminants in diagnostic specimens. Therefore, physicians often tend to consider these organisms as contaminants. However, these microorganisms have increasingly been recognized as pathogens in immunocompromised patients [1]. Corynebacterium amycolatum, in particular, is a common clinical isolate that often shows multidrug resistance to commonly used antibiotics such as β-lactams, macrolides, and fluoroquinolones [2, 3]. In this report, we present a case of bacteremia caused by C. amycolatum possessing a novel mutation in the gyrA gene, which confers high-level quinolone resistance to the organism.

CASE REPORT

An 88-yr-old man with diabetes mellitus presented to our emergency department with chest pain. There was no definite evidence of acute coronary syndrome, but laboratory examination findings indicated impending end-stage renal disease. Hemodialysis was performed through a subclavian double-lumen catheter on alternate days. After 3 sessions of hemodialysis, on the 11th hospital day, the patient developed fever (temperature, 38.0℃), and the blood profile showed a total white blood cell count of 8,800/µL with 74% neutrophils and an elevated C-reactive protein level of 134.2 mg/L. Hence, samples for blood culture were drawn in triplicate, and empiric antibiotic therapy was initiated with 200 mg of ciprofloxacin administered intravenously every 12 hr. On the 14th hospital day, after 72 hr of incubation, "diphtheroid-like organisms" were detected in all 3 aerobic blood-culture bottles. Although the patient had fever and elevated C-reactive protein level, which do indicate bacteremia, the positive blood culture was considered to show merely contaminants, and therefore, additional blood cultures were performed to identify the causative agent. The repeated blood cultures yielded the same results. Therefore, the antibiotic therapy was changed to vancomycin (1 g/day), and the indwelling double-lumen catheter was removed because of suspected catheter-related infection. Follow-up blood cultures were negative, and the patient recovered fully.

1. Identification

Initially, the "diphtheroid-like organisms" were identified as C. diphtheriae by an API Coryne strip (bioMerieux, Marcy l'Etoile, France). Later, 16S rRNA sequence analysis was performed to confirm the species, as described previously [4]. The isolate exhibited 99.1% identity with C. amycolatum CIP 103452T (GenBank accession no.: X82057), and VITEK 2 Anaerobe and Corynebacterium Identification Card (bioMerieux) analysis confirmed the presence of C. amycolatum with a probability of 99.0%.

2. Susceptibility testing

To study the multidrug resistance phenotype of C. amycolatum, we measured the minimum inhibitory concentrations (MICs) of penicillin, ampicillin, imipenem, ciprofloxacin, gentamicin, and vancomycin for this isolate by using Etest (AB bioMerieux, Solna, Sweden). The MIC values are shown in Table 1; ciprofloxacin had the highest MIC value of >32 µg/mL. To elucidate the mechanism underlying the high-level ciprofloxacin resistance, we analyzed the sequence of the quinolone resistance-determining region of the gyrA gene, as described by Sierra et al. [5]. This isolate showed novel mutations in the gyrA gene, wherein the codon for Ser-87 mutated to form an Ile codon and the codon for Asp-91 mutated to a Gly codon (GenBank accession no.:EU835887, Table 2).
Table 1

MIC values for Corynebacterium amycolatum

*in this case; †MIC values were determined in 60 strains of C. amycolatum by using the method described by Gómez-Garcés et al. [6].

Abbreviation: MIC, minimum inhibitory concentration

Table 2

Mutations observed in the quinolone resistance-determining regions of the gyrA gene of Corynebacterium amycolatum isolates and their ciprofloxacin MIC values

*The amino acid position number was obtained from the amino acid sequence of the gyrA gene of Corynebacterium glutamicum; †Data reproduced from Sierra et al. [2].

Abbreviations: MIC, minimum inhibitory concentration; Ser, serine; Ala, alanine; Ile, isoleucine; Tyr, tyrosine; Asp, aspartate; Arg, arginine; Pro, proline; Val, valine; Gly, glycine

DISCUSSION

Although its pathogenic role was apparent only in few cases, C. amycolatum, like Corynebacterium striatum, can cause endocarditis, bacteremia, and catheter exit-site infection. In cases wherein clinically significant infection by any of the coryneform bacteria is suspected, species identification and antibiotic susceptibility determination are important to decide and administer the optimal antibiotic and treatment regimens. However, possibilities like misidentification of species or non-availability of adequate data for using automated kits with identification cards should be considered. Genotypic assays such as 16s rRNA sequencing may be required to confirm the identity of species. In this present case, the clinical isolate showed a high level of resistance to ciprofloxacin (MIC value of >32 µg/mL), probably due to the novel mutation in the gyrA gene, wherein the codon for Ser-87 mutated to form an Ile codon and the codon for Asp-91 mutated to a Gly codon [6]. Therefore, in cases of suspected Corynebacterium spp. infection, the physician and the microbiologists in laboratories should confirm the antibiotic susceptibility patterns of the clinical isolates to help decide the optimal antibiotic and treatment regimens.
  5 in total

Review 1.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

2.  Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum.

Authors:  Josep M Sierra; Luis Martinez-Martinez; Fernando Vázquez; Ernest Giralt; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria.

Authors:  José-Luis Gómez-Garcés; Juan-Ignacio Alos; Javier Tamayo
Journal:  Int J Antimicrob Agents       Date:  2007-05-01       Impact factor: 5.283

4.  Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents.

Authors:  F Soriano; J Zapardiel; E Nieto
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

5.  PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid.

Authors:  K Greisen; M Loeffelholz; A Purohit; D Leong
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

  5 in total
  8 in total

1.  Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.

Authors:  Anna Maria Farca; B Miniscalco; P Badino; R Odore; P Monticelli; A Trisciuoglio; E Ferroglio
Journal:  Parasitol Res       Date:  2012-01-05       Impact factor: 2.289

2.  Corynebacterium striatum-Got Worse by a Pandemic?

Authors:  László Orosz; József Sóki; Dávid Kókai; Katalin Burián
Journal:  Pathogens       Date:  2022-06-14

3.  Conservative treatment of fingertip injuries in children - first experiences with a novel silicone finger cap that enables woundfluid analysis.

Authors:  Jurek Schultz; Percy Schröttner; Susann Leupold; Adrian Dragu; Silvana Sußmann; Michael Haase; Guido Fitze
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2018-10-19

Review 4.  Worldwide survey of Corynebacterium striatum increasingly associated with human invasive infections, nosocomial outbreak, and antimicrobial multidrug-resistance, 1976-2020.

Authors:  Giorgio Silva-Santana; Cecília Maria Ferreira Silva; Julianna Giordano Botelho Olivella; Igor Ferreira Silva; Laís Menegoi Oliveira Fernandes; Bruna Ribeiro Sued-Karam; Cíntia Silva Santos; Cassius Souza; Ana Luíza Mattos-Guaraldi
Journal:  Arch Microbiol       Date:  2021-02-24       Impact factor: 2.552

5.  In vitro Studies of Non-Diphtheriae Corynebacterium Isolates on Antimicrobial Susceptibilities, Drug Resistance Mechanisms, and Biofilm Formation Capabilities.

Authors:  Wei Sun; Liyan Ma; Yana Li; Ying Xu; Jingjuan Wei; Lei Sa; Xinxin Chen; Jianrong Su
Journal:  Infect Drug Resist       Date:  2022-08-09       Impact factor: 4.177

6.  Cytokine Levels in the In Vitro Response of T Cells to Planktonic and Biofilm Corynebacterium amycolatum.

Authors:  Alina Olender; Agnieszka Bogut; Agnieszka Magryś; Jacek Tabarkiewicz
Journal:  Pol J Microbiol       Date:  2019-10-31

7.  Antimicrobial Susceptibility Testing for Corynebacterium Species Isolated from Clinical Samples in Romania.

Authors:  Cristiana Cerasella Dragomirescu; Brandusa Elena Lixandru; Ileana Luminita Coldea; Olguta Nicoleta Corneli; Marina Pana; Andi Marian Palade; Violeta Corina Cristea; Ioana Suciu; George Suciu; Loredana Sabina Cornelia Manolescu; Loredana Gabriela Popa; Mircea Ioan Popa
Journal:  Antibiotics (Basel)       Date:  2020-01-16

8.  Population genomics and antimicrobial resistance in Corynebacterium diphtheriae.

Authors:  Melanie Hennart; Leonardo G Panunzi; Carla Rodrigues; Quentin Gaday; Sarah L Baines; Marina Barros-Pinkelnig; Annick Carmi-Leroy; Melody Dazas; Anne Marie Wehenkel; Xavier Didelot; Julie Toubiana; Edgar Badell; Sylvain Brisse
Journal:  Genome Med       Date:  2020-11-27       Impact factor: 11.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.